RLS

RLS is a pioneering company in the field of molecular imaging, specializing in the provision of predictive and diagnostic radiopharmaceutical products and services. Operating within a 100-mile radius of each of its pharmacies, RLS serves a diverse range of clients, including hospitals, outpatient clinics, and mobile imaging units. The company is the only nationwide radiopharmacy network to have earned The Joint Commission Gold Seal of Approval, a testament to its commitment to quality and safety.

RLS employs a team of highly trained Nuclear Pharmacists and Radiation Safety Officers to ensure the highest standards of service and product integrity. The company’s business model revolves around compounding and dispensing FDA-approved radiopharmaceuticals, ensuring patient safety and maintaining a high accuracy rate of 99.99991% for approximately three million doses dispensed annually.

Revenue is generated through the sale of these specialized imaging products and related therapeutic services. RLS is also expanding its capabilities by incorporating new technologies and enhancing its clean room specifications to meet the growing demands of the market. The company is committed to doubling the size of its network by 2023, further extending its reach and service offerings.

Keywords: radiopharmacy, molecular imaging, predictive diagnostics, FDA-approved, Nuclear Pharmacists, Radiation Safety, real-time tracking, secure sample access, outpatient clinics, mobile imaging.